Nanobiotix S.A. Statistics
Share Statistics
Nanobiotix S.A. has 47.11M shares outstanding. The number of shares has increased by 0% in one year.
Shares Outstanding | 47.11M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 4.96% |
Owned by Institutions (%) | n/a |
Shares Floating | 37.19M |
Failed to Deliver (FTD) Shares | 823 |
FTD / Avg. Volume | 3.79% |
Short Selling Information
The latest short interest is 33.77K, so 0.07% of the outstanding shares have been sold short.
Short Interest | 33.77K |
Short % of Shares Out | 0.07% |
Short % of Float | 0.09% |
Short Ratio (days to cover) | 5.5 |
Valuation Ratios
The PE ratio is -6.15 and the forward PE ratio is -1.6.
PE Ratio | -6.15 |
Forward PE | -1.6 |
PS Ratio | 8.12 |
Forward PS | 4 |
PB Ratio | -132.44 |
P/FCF Ratio | -19.05 |
PEG Ratio | n/a |
Enterprise Valuation
Nanobiotix S.A. has an Enterprise Value (EV) of 218.50M.
EV / Earnings | -5.5 |
EV / Sales | 7.27 |
EV / EBITDA | -7.26 |
EV / EBIT | -8.16 |
EV / FCF | -17.05 |
Financial Position
The company has a current ratio of 1.75, with a Debt / Equity ratio of -24.68.
Current Ratio | 1.75 |
Quick Ratio | 1.75 |
Debt / Equity | -24.68 |
Total Debt / Capitalization | 104.22 |
Cash Flow / Debt | -0.27 |
Interest Coverage | -3.35 |
Financial Efficiency
Return on equity (ROE) is 21.54% and return on capital (ROIC) is -55.13%.
Return on Equity (ROE) | 21.54% |
Return on Assets (ROA) | -0.42% |
Return on Capital (ROIC) | -55.13% |
Revenue Per Employee | 273.25K |
Profits Per Employee | -360.91K |
Employee Count | 110 |
Asset Turnover | 0.32 |
Inventory Turnover | -30.75 |
Taxes
Income Tax | 120.00K |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -47.28% in the last 52 weeks. The beta is 1.4, so Nanobiotix S.A.'s price volatility has been higher than the market average.
Beta | 1.4 |
52-Week Price Change | -47.28% |
50-Day Moving Average | 4.12 |
200-Day Moving Average | 5.32 |
Relative Strength Index (RSI) | 43.17 |
Average Volume (20 Days) | 21.73K |
Income Statement
In the last 12 months, Nanobiotix S.A. had revenue of $30.06M and earned -$39.70M in profits. Earnings per share was $-1.08.
Revenue | 30.06M |
Gross Profit | 30.06M |
Operating Income | -26.78M |
Net Income | -39.70M |
EBITDA | -30.09M |
EBIT | -26.78M |
Earnings Per Share (EPS) | -1.08 |
Balance Sheet
The company has $75.28M in cash and $50.56M in debt, giving a net cash position of $24.72M.
Cash & Cash Equivalents | 75.28M |
Total Debt | 50.56M |
Net Cash | 24.72M |
Retained Earnings | -39.70M |
Total Assets | 86.68M |
Working Capital | 23.94M |
Cash Flow
In the last 12 months, operating cash flow was -$12.48M and capital expenditures -$337.00K, giving a free cash flow of -$12.81M.
Operating Cash Flow | -12.48M |
Capital Expenditures | -337.00K |
Free Cash Flow | -12.81M |
FCF Per Share | -0.35 |
Margins
Gross margin is 120.46%, with operating and profit margins of -89.09% and -132.08%.
Gross Margin | 120.46% |
Operating Margin | -89.09% |
Pretax Margin | -131.68% |
Profit Margin | -132.08% |
EBITDA Margin | -100.09% |
EBIT Margin | -89.09% |
FCF Margin | -42.63% |
Dividends & Yields
NBTX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -32.83% |
FCF Yield | -8.26% |
Analyst Forecast
The average price target for NBTX is $12, which is 264.7% higher than the current price. The consensus rating is "Buy".
Price Target | $12 |
Price Target Difference | 264.7% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Scores
Altman Z-Score | -4.61 |
Piotroski F-Score | 4 |